Susquehanna International Group, LLP Corvus Pharmaceuticals, Inc. Put Options Transaction History

Susquehanna International Group, LLP

6 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	BUY	$1.78 - $5.92 $53,400 - $177,600	30,000 Added 208.33%	44,400 $234,000
Q2 2024 Aug 15, 2024	SELL	$1.36 - $2.29 $12,376 - $20,839	-9,100 Reduced 38.72%	14,400 $26,000
Q1 2024 May 07, 2024	SELL	$1.76 - $2.41 $31,504 - $43,139	-17,900 Reduced 43.24%	23,500 $41,000
Q4 2023 Feb 14, 2024	SELL	$1.08 - $1.92 $12,960 - $23,040	-12,000 Reduced 22.47%	41,400 $72,000
Q3 2023 Nov 14, 2023	SELL	$1.41 - $2.97 $30,315 - $63,855	-21,500 Reduced 28.7%	53,400 $77,000
Q2 2023 Aug 11, 2023	BUY	$1.0 - $3.86 $74,900 - $289,114	74,900 New	74,900 $171,000

30.4M

1.06M

84.3K

Ticker CRVS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,553,500
Market Cap $242M
Description
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The compan...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.